|
|
|
Size
|
Re: Non-RCT designs & causation
|
Shaughnessy, Allen |
Mon, 31 May 2021 18:22:27 -0400 |
189 lines |
Re: Non-RCT designs & causation
|
McCormack, James |
Mon, 31 May 2021 15:56:43 +0000 |
194 lines |
Re: Non-RCT designs & causation
|
Rakesh Biswas |
Mon, 31 May 2021 20:29:03 +0530 |
163 lines |
Re: Non-RCT designs & causation
|
Anoop B |
Mon, 31 May 2021 08:26:31 -0400 |
120 lines |
Non-RCT designs & causation
|
David Nunan |
Mon, 31 May 2021 09:51:27 +0000 |
28 lines |
Re: prioritization of resource allocation ...
|
Wouter Havinga |
Mon, 31 May 2021 07:33:24 +0100 |
1550 lines |
prioritization of resource allocation ...
|
Benjamin Djulbegovic MD |
Sun, 30 May 2021 13:22:55 +0000 |
616 lines |
Re: Inappropriate comparators
|
Wouter Havinga |
Sun, 30 May 2021 00:19:49 +0100 |
603 lines |
Re: Looking for articles documenting inconsistencies between "evidence-based" guidelines on the same topic
|
OWEN DEMPSEY |
Sat, 29 May 2021 20:52:17 +0100 |
299 lines |
Re: Inappropriate comparators
|
Benjamin Djulbegovic MD |
Sat, 29 May 2021 12:31:08 +0000 |
363 lines |
Re: Looking for articles documenting inconsistencies between "evidence-based" guidelines on the same topic
|
Wouter Havinga |
Sat, 29 May 2021 13:16:56 +0100 |
711 lines |
Re: Inappropriate comparators
|
David Richard Leslie Cawthorpe |
Sat, 29 May 2021 10:49:19 +0000 |
249 lines |
Re: Inappropriate comparators
|
Wouter Havinga |
Sat, 29 May 2021 11:22:08 +0100 |
139 lines |
Re: Inappropriate comparators
|
Joshua Davis |
Fri, 28 May 2021 11:46:37 -0500 |
210 lines |
Re: Inappropriate comparators
|
Luiza de Oliveira Rodrigues |
Fri, 28 May 2021 11:50:07 -0300 |
141 lines |
Research vacancies at University of Glasgow Health Economics and Health Technology Assessment (HEHTA) Group
|
Alieda McKinney |
Fri, 28 May 2021 13:18:37 +0000 |
240 lines |
Inappropriate comparators
|
Jeremy Howick |
Fri, 28 May 2021 12:41:16 +0000 |
103 lines |
Re: Looking for articles documenting inconsistencies between "evidence-based" guidelines on the same topic
|
Bewley, Susan |
Fri, 28 May 2021 11:55:30 +0000 |
557 lines |
Re: Looking for articles documenting inconsistencies between "evidence-based" guidelines on the same topic
|
Michael Power |
Thu, 27 May 2021 21:17:58 +0100 |
585 lines |
Re: Looking for articles documenting inconsistencies between "evidence-based" guidelines on the same topic
|
Jon Brassey |
Thu, 27 May 2021 12:39:41 +0100 |
523 lines |
Re: Looking for articles documenting inconsistencies between "evidence-based" guidelines on the same topic
|
Michael Power |
Thu, 27 May 2021 12:10:49 +0100 |
606 lines |
Re: Looking for articles documenting inconsistencies between "evidence-based" guidelines on the same topic
|
Wouter Havinga |
Thu, 27 May 2021 10:26:41 +0100 |
463 lines |
Re: Looking for articles documenting inconsistencies between "evidence-based" guidelines on the same topic
|
David Nunan |
Thu, 27 May 2021 08:27:49 +0000 |
254 lines |
Re: Looking for articles documenting inconsistencies between "evidence-based" guidelines on the same topic
|
Michael Power |
Thu, 27 May 2021 08:52:58 +0100 |
185 lines |
Re: Looking for articles documenting inconsistencies between "evidence-based" guidelines on the same topic
|
Brian Alper |
Wed, 26 May 2021 09:46:26 +0000 |
93 lines |
Looking for articles documenting inconsistencies between "evidence-based" guidelines on the same topic
|
Michael Power |
Wed, 26 May 2021 08:01:36 +0100 |
35 lines |
Healthy Cities: India and the Global South
|
Dennis Jackson |
Tue, 25 May 2021 15:55:32 +0100 |
118 lines |
Call for Abstracts – NVivo Virtual Conference 2021 – Deadline June 30
|
Silvana di Gregorio |
Tue, 25 May 2021 09:14:19 +0000 |
111 lines |
2nd Evidence-Based Research Conference
|
Caroline Blaine |
Fri, 21 May 2021 15:28:14 +0100 |
110 lines |
Re: Using ARR to compare Risks and Benefits
|
Marco Tullio Suadoni |
Fri, 21 May 2021 13:09:48 +0100 |
239 lines |
Re: Using ARR to compare Risks and Benefits
|
Marco Tullio Suadoni |
Fri, 21 May 2021 12:43:28 +0100 |
116 lines |
Re: Using ARR to compare Risks and Benefits
|
Benjamin Djulbegovic MD |
Wed, 19 May 2021 15:50:23 +0000 |
1257 lines |
Re: Using ARR to compare Risks and Benefits
|
Anoop B |
Wed, 19 May 2021 11:18:01 -0400 |
1489 lines |
Re: Using ARR to compare Risks and Benefits
|
Benjamin Djulbegovic MD |
Wed, 19 May 2021 12:45:06 +0000 |
1253 lines |
Re: Using ARR to compare Risks and Benefits
|
Puliyel |
Wed, 19 May 2021 15:31:12 +0530 |
1223 lines |
Re: Using ARR to compare Risks and Benefits
|
David Nunan |
Wed, 19 May 2021 06:12:12 +0000 |
713 lines |
Re: Using ARR to compare Risks and Benefits
|
Lyndal Trevena |
Wed, 19 May 2021 02:21:28 +0000 |
558 lines |
Re: Using ARR to compare Risks and Benefits
|
christoph schnelle |
Wed, 19 May 2021 02:09:18 +0000 |
480 lines |
Re: Using ARR to compare Risks and Benefits
|
Benjamin Djulbegovic MD |
Tue, 18 May 2021 20:25:28 +0000 |
457 lines |
Re: Using ARR to compare Risks and Benefits
|
Puliyel |
Wed, 19 May 2021 01:47:37 +0530 |
208 lines |
Using ARR to compare Risks and Benefits
|
Puliyel |
Tue, 18 May 2021 18:44:15 +0530 |
79 lines |
Re: Net benefit and decision curve analysis
|
Anoop B |
Sat, 15 May 2021 23:13:36 -0400 |
1372 lines |
Re: Net benefit and decision curve analysis
|
Rakesh Biswas |
Sat, 15 May 2021 09:09:48 +0530 |
1370 lines |
Re: Net benefit and decision curve analysis
|
McCormack, James |
Fri, 14 May 2021 17:32:29 +0000 |
924 lines |
Re: Net benefit and decision curve analysis
|
Anoop B |
Fri, 14 May 2021 09:21:20 -0400 |
1197 lines |
Re: Net benefit and decision curve analysis
|
Benjamin Djulbegovic MD |
Fri, 14 May 2021 13:11:38 +0000 |
1196 lines |
Re: Net benefit and decision curve analysis
|
McCormack, James |
Fri, 14 May 2021 04:43:33 +0000 |
1171 lines |
Re: Net benefit and decision curve analysis
|
christoph schnelle |
Fri, 14 May 2021 04:35:20 +0000 |
851 lines |
Re: Net benefit and decision curve analysis
|
David Richard Leslie Cawthorpe |
Fri, 14 May 2021 04:21:56 +0000 |
307 lines |
Re: Net benefit and decision curve analysis
|
McCormack, James |
Fri, 14 May 2021 04:21:23 +0000 |
858 lines |
Re: Net benefit and decision curve analysis
|
Benjamin Djulbegovic MD |
Fri, 14 May 2021 01:28:54 +0000 |
971 lines |
Re: Net benefit and decision curve analysis
|
McCormack, James |
Thu, 13 May 2021 22:43:43 +0000 |
673 lines |
Re: Net benefit and decision curve analysis
|
Benjamin Djulbegovic MD |
Thu, 13 May 2021 21:48:44 +0000 |
409 lines |
Re: Net benefit and decision curve analysis
|
Michael Power |
Thu, 13 May 2021 22:16:22 +0100 |
369 lines |
Cfp - Italian Society for the Sociology of Health (SISS)
|
Dennis Jackson |
Thu, 13 May 2021 16:31:08 +0100 |
74 lines |
Upcoming courses in JUNE 2021 from Imperial College London
|
Krupa Shukla |
Thu, 13 May 2021 15:06:25 +0100 |
139 lines |
Re: Net benefit and decision curve analysis
|
Benjamin Djulbegovic MD |
Thu, 13 May 2021 12:28:06 +0000 |
278 lines |
Net benefit and decision curve analysis
|
Michael Power |
Thu, 13 May 2021 08:56:00 +0100 |
73 lines |
Re: Masking Paper
|
Dr Amy Price |
Wed, 12 May 2021 21:05:24 -0400 |
317 lines |
Re: Masking Paper
|
Kumara Mendis |
Thu, 13 May 2021 06:21:42 +0530 |
165 lines |
Masking Paper
|
Dr Amy Price |
Wed, 12 May 2021 13:55:18 -0400 |
103 lines |
Advanced Evidence & Knowledge Analyst vacancies with Public Health Wales
|
Fiona Morgan (Public Health Wales - No. 2 Capital Quarter) |
Wed, 12 May 2021 10:34:11 +0000 |
197 lines |
LAST FEW PLACES REMAINING FOR: advanced searching for systematic reviews courses: unpublished trial data / trials registers - and citation analysis
|
Carol Lefebvre |
Mon, 10 May 2021 18:26:29 +0000 |
621 lines |
Free special issue preview from Evidence & Policy
|
Thea Cook |
Mon, 10 May 2021 10:45:34 +0100 |
118 lines |
Re: Solidarity in Kindness
|
Dr Amy Price |
Thu, 6 May 2021 23:11:02 -0400 |
959 lines |
LAST FEW PLACES REMAINING: Advanced Searching for Systematic Reviews, HTA and Guideline Development: Techniques and Resources - May 2021
|
Carol Lefebvre |
Thu, 6 May 2021 16:29:23 +0000 |
470 lines |
Re: Solidarity in Kindness
|
Angela Benfield |
Tue, 4 May 2021 08:42:18 -0500 |
937 lines |
Re: Solidarity in Kindness
|
Oliver Fisher |
Tue, 4 May 2021 22:01:18 +1000 |
1009 lines |
Re: Dexamethasone for COVID and FDA
|
Kumara Mendis |
Mon, 3 May 2021 18:36:00 +0530 |
624 lines |
Re: Dexamethasone for COVID and FDA
|
Benjamin Djulbegovic MD |
Sun, 2 May 2021 20:49:31 +0000 |
273 lines |
Re: Dexamethasone for COVID and FDA
|
Anoop B |
Sun, 2 May 2021 16:31:24 -0400 |
156 lines |
Re: Dexamethasone for COVID and FDA
|
Benjamin Djulbegovic MD |
Sun, 2 May 2021 20:03:42 +0000 |
533 lines |
Re: Dexamethasone for COVID and FDA
|
Michael Power |
Sun, 2 May 2021 17:12:34 +0100 |
100 lines |
Re: Dexamethasone for COVID and FDA
|
Vivek Podder |
Sun, 2 May 2021 21:21:20 +0600 |
433 lines |
Re: Dexamethasone for COVID and FDA
|
Benjamin Djulbegovic MD |
Sun, 2 May 2021 14:31:37 +0000 |
369 lines |
Re: Dexamethasone for COVID and FDA
|
Anoop B |
Sun, 2 May 2021 09:43:18 -0400 |
279 lines |
Re: Oxygen for India- An Appeal to the International Community
|
Marilyn Mann |
Sun, 2 May 2021 09:38:48 -0400 |
426 lines |
FW: Oxygen for India- An Appeal to the International Community
|
Dr Amy Price |
Sun, 2 May 2021 09:13:53 -0400 |
225 lines |
Re: Dexamethasone for COVID and FDA
|
Benjamin Djulbegovic MD |
Sun, 2 May 2021 13:05:05 +0000 |
245 lines |
Dexamethasone for COVID and FDA
|
Anoop Balachandran |
Sun, 2 May 2021 13:06:14 +0100 |
30 lines |